Q1 2021 13F Holders as of 31 Mar 2021
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
54,711,345
-
Number of holders
-
104
-
Total 13F shares, excl. options
-
38,422,385
-
Shares change
-
-224,871
-
Total reported value, excl. options
-
$1,492,282,987
-
Value change
-
-$15,747,693
-
Put/Call ratio
-
1.44%
-
Number of buys
-
54
-
Number of sells
-
-38
-
Price
-
$38.84
Significant Holders of Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) as of Q1 2021
126 filings reported holding STOK - Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share as of Q1 2021.
Stoke Therapeutics, Inc. - Common Stock, $0.0001 par value per share (STOK) has 104 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 38,422,385 shares
of 54,711,345 outstanding shares and own 70.23% of the company stock.
Largest 10 shareholders include ATP Life Science Ventures, L.P. (17,161,713 shares), RTW INVESTMENTS, LP (3,644,248 shares), FMR LLC (2,877,566 shares), Redmile Group, LLC (2,544,062 shares), VANGUARD GROUP INC (1,661,011 shares), BlackRock Inc. (1,660,112 shares), Cormorant Asset Management, LP (1,437,807 shares), GILDER GAGNON HOWE & CO LLC (1,265,950 shares), FEDERATED HERMES, INC. (872,264 shares), and STATE STREET CORP (747,288 shares).
This table shows the top 104 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.